Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Olanzapine in Patients With Borderline Personality Disorder

This study has been completed.
Sponsor:
Information provided by:
Eli Lilly and Company
ClinicalTrials.gov Identifier:
NCT00091650
First received: September 14, 2004
Last updated: July 21, 2006
Last verified: July 2006